Corrigendum to 'Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Annals of Oncology Volume 31, Issue 6, June 2020, Pages 697-712] [0.03%]
成人急性髓系白血病诊断、治疗和随访：ESMO临床实践指南（对2020年6月版的更正）
M Heuser,Y Ofran,N Boissel et al.
M Heuser et al.
IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy [0.03%]
IgE阻断在治疗与医学肿瘤疗法相关的嗜酸性粒细胞相关难治性瘙痒中的应用
R Gutzmer,V Sibaud,J C Hassel
R Gutzmer
Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials? [0.03%]
癌症患者接受抗程序性细胞死亡蛋白1免疫治疗后出现多种免疫相关不良事件：可能是临床试验中的新替代标志物？
A Laparra,M Kfoury,S Champiat et al.
A Laparra et al.
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ [0.03%]
小细胞肺癌：诊断、治疗和随访的ESMO临床实践指南
A-M C Dingemans,M Früh,A Ardizzoni et al.
A-M C Dingemans et al.
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020 [0.03%]
美国癌症患者针对基因组靶向药物适用性和反应的最新估计，2006-2020年
A Haslam,M S Kim,V Prasad
A Haslam
Background: Prior studies have evaluated the percentage of cancer patients with advanced or metastatic cancer who are eligible for and respond to genome-targeted therapy, but since that publication, the number of Food and...
Circulating tumor DNA in patients with metastatic prostate cancer treated with abiraterone acetate [0.03%]
醋酸阿比特龙治疗转移性前列腺癌患者的循环肿瘤DNA
Y Loriot,K Fizazi
Y Loriot
How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy [0.03%]
PD-1/PD-L1抑制剂的研发及其生物标志物探索
A Fundytus,C M Booth,I F Tannock
A Fundytus
Building bridges between drug development and cancer science: a tribute to José Baselga's legacy [0.03%]
连接药物开发与癌症研究的桥梁：致敬José Baselga的遗产
D M Hyman,J-C Soria,J Tabernero
D M Hyman
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial [0.03%]
卡巴他赛与阿比特龙或恩杂鲁胺治疗预后较差的转移性去势抵抗性前列腺癌：一项多中心、随机、开放标签Ⅱ期临床试验
M Annala,S Fu,J V W Bacon et al.
M Annala et al.
Background: Treatment of poor prognosis metastatic castration-resistant prostate cancer (mCRPC) includes taxane chemotherapy and androgen receptor pathway inhibitors (ARPI). We sought to determine optimal treatment in thi...
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines [0.03%]
BRAF突变转移性结直肠癌的治疗：治疗方法及循证指南点评
A Grothey,M Fakih,J Tabernero
A Grothey
Background: Colorectal cancer (CRC) is still a leading cause of cancer-related deaths in the United States and worldwide, despite recent improvements in cancer management. CRC, like many malignancies, is a heterogeneous d...